Title: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels
Abstract: Source of Review The Institute for Clinical and Economic Review developed an evidence report, including a systematic reviewof the literature, a costeffectiveness model, and a budget impact assessment, to support a public meeting of the New EnglandComparativeEffectiveness Public Advisory Council (CEPAC) on October 27, 2015.1 The report evaluates the comparative clinical effectiveness and comparative value of proprotein convertase subtilisin/ kexin type9 (PCSK9) inhibitors as a class for the treatmentof adults with familial hypercholesterolemiaor cardiovascular disease (CVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C) levels.
Publication Year: 2016
Publication Date: 2016-01-01
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 43
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot